Miraculous Recovery of Hypoxemic COVID-19 Patients With Ivermectin

Unhooking spike hemagglutinated red blood cells

The past three years have generated millions of case vignettes of patients with COVID-19 respiratory illness. The most dramatic cases include critically ill inpatients with severe hypoxemia despite maximum respiratory support.

By far, the most notable cases of survival have occurred with the administration of ivermectin. Former NIH researcher David Scheim, PhD, early in the pandemic proposed that SARS-CoV-2 Spike protein was acting like a grappling hook pulling together circulating red blood cells into long chains and clumps in a process called hemagglutination. This explained why the red blood cells could not carry oxygen normally and was congruent with the finding of micro blood clots in the lungs. Recently, Boschi et al have provided additional support for this mechanism.[i] In a spectacular publication, Stone et al, describes the prompt improvement of oxygenation in patients with ivermectin.[ii]

Stone JC, Ndarukwa P, Scheim DE, Dancis BM, Dancis J, et al. Changes in SpO2 on Room Air for 34 Severe COVID-19 Patients after Ivermectin-Based Combination Treatment: 62% Normalization within 24 Hours. Biologics. 2022;2(3):196-210

The published oxygenation curves from multiple studies clearly show this physiological effect of ivermectin occurs so rapidly, it must be explained by a direct anti-Spike protein effect of ivermectin. An anonymous video of a critically ill man demonstrates the very effect that Scheim, Stone, Hazan, and Babalola have described in the Figure.[iii]  So for the next critically ill patient with COVID-19, if the opportunity presents itself, push for the administration of ivermectin.  This is the only published therapy for COVID-19 that improves oxygen saturation while the patient mounts a recovery.   As in this man, it may be the critical factor for a turnaround and a chance to walk out of the hospital.

Reposted from the author’s Substack


[i] SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects Celine Boschi, David E. Scheim, Audrey Bancod, Muriel Millitello, Marion Le Bideau, Philippe Colson, Jacques Fantini, Bernard La Scola bioRxiv 2022.11.24.517882; doi: https://doi.org/10.1101/2022.11.24.517882

[ii] Stone, J.C.; Ndarukwa, P.; Scheim, D.E.; Dancis, B.M.; Dancis, J.; Gill, M.G.; Aldous, C. Changes in SpO2 on Room Air for 34 Severe COVID-19 Patients after Ivermectin-Based Combination Treatment: 62% Normalization within 24 Hours. Biologics 2022, 2, 196-210. https://doi.org/10.3390/biologics2030015

[iii] This well constructed case demonstrates recovery from COVID-19 respiratory illness and advanced hypoxemia with inpatient ivermectin.

Views expressed in this article are the opinions of the author and do not necessarily reflect the views of The Epoch Times. Epoch Health welcomes professional discussion and friendly debate. To submit an opinion piece, please follow these guidelines and submit through our form here.

Dr. McCullough is a practicing internist, cardiologist, and epidemiologist in Dallas, Texas. He studies the cardiovascular complications of both the viral infection and the injuries developed from COVID vaccines. He has dozens of peer-reviewed publications on COVID, multiple U.S. and state Senate testimonies, and has commented extensively on the medical response to the COVID crisis on major media outlets.
John Leake studied history and philosophy with Roger Scruton at Boston University. He then went to Vienna, Austria on a graduate school scholarship and ended up living in the city for over a decade, working as a freelance writer and translator. He is a true crime writer with a lifelong interest in medical history and forensic medicine.
You May Also Like